CLAIMS

1. An anti-Siglec-10 antibody, wherein the antibody comprises (a) a heavy chain variable region comprising one or more of a complementarity determining region (CDR) 1 comprising the sequence set forth in SEQ ID NO: 3, a CDR2 comprising the sequence set forth in SEQ ID NO: 4, and a CDR3 comprising the sequence set forth in SEQ ID NO: 5; and, (b) a light chain variable region comprising one or more of a CDR1 comprising the sequence set forth in SEQ ID NO: 6, a CDR2 comprising the sequence set forth in SEQ ID NO: 7, and a CDR3 comprising the sequence set forth in SEQ ID NO: 8.

2. The anti-Siglec-10 antibody of claim 1, wherein the heavy chain variable region comprises the sequence set forth in SEQ ID NO: 1 and the light chain variable region comprises the sequence set forth in SEQ ID NO: 2.

3. The anti-Siglec-10 antibody of claim 1 or 2, wherein the antibody is a chimeric antibody.

4. The anti-Siglec-10 antibody of claim 1, wherein the heavy chain variable region comprises the sequence set forth in one of SEQ ID NOS: 9-13, and the light chain variable region comprises the sequence set forth in one of SEQ ID NOS: 14-18.

5. The anti-Siglec-10 antibody of claim 4, wherein the heavy chain variable region comprises the sequence set forth in SEQ ID NO: 9, 10, or 11, and the light chain variable region comprises the sequence set forth in SEQ ID NO: 15.

6. The anti-Siglec-10 antibody of claim 5, wherein the heavy chain variable region comprises the sequence set forth in SEQ ID NO: 9.

7. The anti-Siglec-10 antibody of claim 6, wherein the heavy chain comprises the sequence set forth in SEQ ID NO: 25.

8. The anti-Siglec-10 antibody of claim 7, wherein the light chain comprises the sequence set forth in SEQ ID NO: 27.

9. The anti-Siglec-10 antibody of claim 5, wherein the heavy chain variable region comprises the sequence set forth in SEQ ID NO: 10.

10. The anti-Siglec-10 antibody of claim 9, wherein the heavy chain comprises the sequence set forth in SEQ ID NO: 32.

11. The anti-Siglec-10 antibody of claim 10, wherein the light chain comprises the sequence set forth in SEQ ID NO: 27.

12. The anti-Siglec-10 antibody of claim 5, wherein the heavy chain variable region comprises the sequence set forth in SEQ ID NO: 11.

13. The anti-Siglec-10 antibody of claim 4, wherein the heavy chain variable region comprises the sequence set forth in SEQ ID NO: 10 or 12, and the light chain variable region comprises the sequence set forth in SEQ ID NO: 17.

14. The anti-Siglec-10 antibody of claim 13, wherein the heavy chain variable region comprises the sequence set forth in SEQ NO: 10.

15. The anti-Siglec-10 antibody of claim 13, wherein the heavy chain variable region comprises the sequence set forth in SEQ NO: 12.

16. The anti-Siglec-10 antibody of claim 4, wherein the heavy chain variable region comprises the sequence set forth in SEQ ID NO: 10 or 12, and the light chain variable region comprises the sequence set forth in SEQ ID NO: 16.

17. The anti-Siglec-10 antibody of claim 16, wherein the heavy chain variable region comprises the sequence set forth in SEQ ID NO: 10.

18. The anti-Siglec-10 antibody of claim 17, wherein the heavy chain comprises the sequence set forth in SEQ ID NO: 32.

19. The anti-Siglec-10 antibody of claim 18, wherein the light chain comprises the sequence set forth in SEQ ID NO: 34.

20. The anti-Siglec-10 antibody of claim 16, wherein the heavy chain variable region comprises the sequence set forth in SEQ ID NO: 12.

21. An anti-Siglec-10 antibody, wherein the heavy chain comprises the sequence set forth in SEQ ID NO: 32 and the light chain comprises the sequence set forth in SEQ ID NO: 27; the heavy chain comprises the sequence set forth in SEQ ID NO: 25 and the light chain comprises the sequence set forth in SEQ ID NO: 27; or the heavy chain comprises the sequence set forth in SEQ ID NO: 32 and the light chain comprises the sequence set forth in SEQ ID NO: 34.

22. Use of the anti-Siglec-10 antibody of any one of claims 1-21 in the manufacture of a medicament for treating cancer.

23. The use of claim 22, wherein the medicament is intended for use in combination with a second cancer therapy.

24. The use of claim 23, wherein the second cancer therapy is a cancer-targeting immunotherapy or an immune-cell-targeting immunotherapy.

25. The use of claim 24, wherein the second cancer therapy is an anti-CTLA-4 antibody.

26. The use of any one of claims 22-25, wherein the cancer is an advanced solid tumor, a hematologic cancer, or a cancer that includes infiltrating cells that bind to the anti-Siglec-10 antibody.

27. The use of claim 26, wherein the cancer is an advanced solid tumor selected from the group consisting of lung adenocarcinoma (LUAD), a skin cutaneous melanoma–metastasis (SKCM-TM), a lung squamous cell carcinoma (LUSC), a breast invasive carcinoma—basal, a breast invasive carcinoma—Her2, a pancreatic adenocarcinoma, a head and neck squamous cell carcinoma, a kidney renal clear cell carcinoma, a stomach adenocarcinoma, a glioblastoma multiforme, a breast invasive carcinoma—LumB, or a breast invasive carcinoma—LumA, a non-small cell lung cancer, a glioblastoma, a melanoma, a low grade glioma, a kidney cancer, a breast cancer basal type, a Her2+ breast cancer, a pancreatic cancer, and an ovarian cancer.

28. The use of claim 27, wherein the lung adenocarcinoma is a non-small cell lung adenocarcinoma.

29. The use of claim 26, wherein the cancer is a hematologic cancer selected from the group consisting of a leukemia, a myeloid dysplasia syndrome, a B cell lymphoma, and a multiple myeloma.